anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endobronchial ultrasound-guided transbronchial needle aspiration which is known as the EBUS procedure is a low risk procedure performed using bronchoscopy to sample chest lesions. A needle is passed through the bronchoscope to biopsy the chest lesion. Every lesion is usually biopsied 3 to 7 times. In most cases the investigators apply a syringe with negative pressure to the needle inserted into lesion for biopsy. In some cases the investigators don't apply any negative pressure. There are no studies to evaluate which one is better, applying syringe suction or no suction.

In our study, the investigators are planning to do biopsies with or without suction. Then, the pathology samples will be evaluated for any cytologic difference in making the diagnosis. Any patient undergoing the EBUS procedure for chest biopsies will be eligible. Every lesion will be biopsied at least twice with needle with and without suction. The biopsy samples will be then divided into group A where the investigators applied syringe suction and group B where no syringe suction was applied. There is no risk to the patient in addition to the risk of the EBUS procedure itself. The investigators are not performing any additional intervention from the usual standard of care for any patient presenting for the EBUS procedure. Essentially the investigators are simply grouping the suction and no suction pathology samples as A and B for pathologic comparison.

RESULTS: Among the 26 participants, one of the patients (3.8%) had no adequate tissue using both methods; one patient (3.8%) had adequate tissue using suction but no adequate tissue using no suction; and 24 patients had adequate tissue using both methods (92.3%, p= 1.00). Among the twenty-four patients with adequate tissue using both methods, 14 patients (58.3%) had benign pathology using both methods, while ten patients (41.7%) had malignant pathology using both methods (p= 1.00). Considering suction to be the golden method, the sensitivity and specificity of no suction were 100%. Among the 32 sites that were sampled, one site (3.1%) had no adequate tissue using both methods; one site (3.1%) had adequate tissue using suction but no adequate tissue using no suction; and 30 sites had adequate tissue using both methods (93.8%, p= 1.00). Among the thirty sites with adequate tissue using both methods, 17 (56.7%) had benign pathology using both methods; 12 (40.0%) had malignant pathology using both methods; and one site (3.3%) had malignant pathology using suction, but benign pathology using no suction (p= 1.00). Considering suction to be the golden method, the no suction had a sensitivity= 92.3% and specificity= 100%.
This scoping review aims to identify and evaluate the landscape of Polygenic Risk Score (PRS)-based methods for genomic prediction from 2013 to 2023, highlighting their advancements, key concepts, and existing gaps in knowledge, research, and technology. Over the past decade, various PRS-based methods have emerged, each employing different statistical frameworks aimed at enhancing prediction accuracy, processing speed and memory efficiency. Despite notable advancements, challenges persist, including unrealistic assumptions regarding sample sizes and the polygenicity of traits necessary for accurate predictions, as well as limitations in exploring hyper-parameter spaces and considering environmental interactions. We included studies focusing on PRS-based methods for risk prediction that underwent methodological evaluations using valid approaches and released computational tools/software. Additionally, we restricted our selection to studies involving human participants that were published in English language. This review followed the standard protocol recommended by Joanna Briggs Institute Reviewer's Manual, systematically searching Ovid MEDLINE, Ovid Embase, Scopus and Web of Science databases. Additionally, searches included grey literature sources like pre-print servers such as bioRxiv, and articles recommended by experts to ensure comprehensive and diverse coverage of relevant records. This study identified 34 studies detailing 37 genomic prediction methods, the majority of which rely on linkage disequilibrium (LD) information and necessitate hyper-parameter tuning. Nine methods integrate functional/gene annotation, while 12 are suitable for cross-ancestry genomic prediction, with only one considering gene-environment (GxE) interaction. While some methods require individual-level data, most leverage summary statistics, offering flexibility. Despite progress, challenges remain. These include computational complexity and the need for large sample sizes for high prediction accuracy. Furthermore, recent methods exhibit varying effectiveness across traits, with absolute accuracies often falling short of clinical utility. Transferability across ancestries varies, influenced by trait heritability and diversity of training data, while handling admixed populations remains challenging. Additionally, the absence of standard error measurements for individual PRSs, crucial in clinical settings, underscores a critical gap. Another issue is the lack of customizable graphical visualization tools among current software packages. While genomic prediction methods have advanced significantly, there is still room for improvement. Addressing current challenges and embracing future research directions will lead to the development of more universally applicable, robust, and clinically relevant genomic prediction tools.
A physical and mental health status monitor, analyze and follow up clothing system. Whose purpose is to monitor the user's body fat distribution, muscular activity and position changes to diagnose health status. Regularly giving suggestions to the user to achieve proper exercise and posture to reduce body fat and prevent muscular atrophy. While correcting the user's life style to promote better health, this system also works to reduce mental and emotional stress. Providing better healthcare and reducing the chance of disease. This system includes sensors, a close range monitoring system and long range monitoring stations, through the sensors it collects data for the monitoring system and monitoring stations to observe, analyze, diagnose and follow up on the user's physical and mental state. This system also allows the user and the long range monitoring stations to communicate with each other through the close range monitoring system.
This is a non-interventional, prospective, open-label, single-arm, 3-cohort, multicenter study in Germany and Austria. In total, 606 patients will be enrolled in approx. 120 oncological sites (office-based medical oncologists, oncology outpatient-centers, and university hospitals) in a time period of 48 months. Of these, 202 patients with high risk, 202 patients with intermediate risk, and 202 patients with low risk, as a priori assessed by the metastatic colorectal cancer prognostic score (mCCS), will be included. Overall survival of the pre-defined prognostic groups will be analyzed as primary endpoint to validate the mCCS.

Patients have been scheduled to receive first line combination therapy with panitumumab and FOLFIRI or FOLFOX according to the current SmPC valid for Germany and Austria, respectively. Data on efficacy in terms of tumor response evaluation / survival and safety (ADRs) will be collected during first line therapy. A subset of patients participating in the 'VALIDATE-PRO' project (n=303) will be assessed for general and health-related quality of life with patient questionnaires. Biomarker status beyond RAS will be collected at baseline. The documentation of defined patient data including survival will continue until the end of the individual study participation which is latest 36 months after last patient in. The end of study will be at latest at 36 months after last patient in (LPI).
The present invention discloses nano ginsenoside particle (Ginsome) and its preparation process and use. Ginsenoside, cholesterol and lecithin in the weight ratio of 20 to 1 to 1 are mixed while adding non-ionic surfactant for assisting dissolution so as to form nanometer particle automatically through the mutual reaction among ginsenoside, cholesterol and lecithin. Then, the non-ionic surfactant is eliminated through dialysis or ultrafiltering to obtain the Ginsome. Electronic microscope observation shows that the Ginsome is spherical particle of 60-80 nm diameter. The Ginsome has function of immunological adjuvant, and can strengthen vaccine induced body fluid immunity and cell immunity function. The Ginsome in the amount of 10 microgram can raise the immunogenicity of antigen obviously and has wide application in vaccine preparation.
This prospective, single-center study was conducted at UnityPoint Health-Meriter Hospital (Madison, WI, USA) in preterm neonates admitted to a level III NICU from April 2018 to August 2019. The primary study aim was to assess changes in RrSO2 with continuous renal NIRS monitoring to detect AKI during the first 7 days of age.

The INVOS 5100 C (Somanetics, Troy, MI, USA) four channel NIRS monitors were used to measure RrSO2 (measured at the right or left flank) and Cerebral regional Somatic tissue Oxygenation (CrSO2; measured at the forehead) for all neonates. At each measurement site, for skin protection, subjects had a transparent Mepitel (with Safetac Technology, Norcross, GA) adhesive dressing placed with the adhesive neonatal NIRS sensor (INVOS OxyAlert NIRSensor, Covidien) adhered over the Mepitel dressing. Neither cerebral or kidney sensors were placed with ultrasound guidance. Tissue oxygenation was recorded every 3 seconds until 7 days of age, and the sensor was changed one time when the patient reached three to four days of age per the company's recommendation. There were no restrictions on positioning or handling of neonates; nurses re-positioned neonates every 3-6 hours per unit protocol to prevent skin pressure injuries. Researchers, staff, and parents were blinded to RrSO2 values.
OBJECTIVE: This retrospective study aimed to investigate how congenital heart disease (CHD) affects early neonatal outcomes by comparing Apgar scores and umbilical cord blood gas parameters between fetuses with structural cardiac anomalies and healthy controls. Additionally, within the CHD group, the study explored the relationship between these parameters and mortality within six months.
METHODS: Data from 68 cases of prenatally diagnosed CHD were collected from electronic medical records, excluding cases with missing data or additional comorbidities. Only patients delivered by elective cesarean section, without any attempt at labor, were analyzed to avoid potential confounding factors. A control group of 147 healthy newborns was matched for delivery route, maternal age, and gestational week. Apgar scores at 1, 5, and 10 minutes, as well as umbilical cord blood pH, base deficit, and lactate levels, were recorded.
RESULTS: Maternal age, gestational week at delivery, and birth weight were similar between the CHD and control groups. While Apgar score distribution was significantly lower at 1st, 5th, and 10th minutes in the CHD group, umbilical cord blood gas parameters did not show significant differences between groups. Within the CHD group, lower umbilical cord blood pH and larger base deficit were associated with mortality within six months.
CONCLUSION: Newborns with CHD exhibit lower Apgar scores compared to healthy controls, suggesting potential early neonatal challenges. Furthermore, umbilical cord blood pH and base deficit may serve as predictors of mortality within six months in CHD cases. Prospective studies are warranted to validate these findings and integrate them into clinical practice, acknowledging the study's retrospective design and limitations.
ADLARITY is supplied in cartons, with each carton containing four transdermal systems that are individually packaged in sealed pouches.

• The ADLARITY 5 mg/day adhesive transdermal system is rectangular in shape, with rounded corners, measuring 8.3 cm by 10.8 cm, and containing 97 mg of donepezil hydrochloride. Each transdermal system has a tan colored backing with the ADLARITY (donepezil transdermal system) logo and 5 mg/day printed in black on the non-adhesive side. ADLARITY 5 mg/day is available in a carton of 4 (NDC 65038-055-03).

• The ADLARITY 10 mg/day adhesive transdermal system is rectangular in shape, with rounded corners, measuring 10.8 cm by 14.4 cm, and containing 194 mg of donepezil hydrochloride. Each transdermal system has a tan colored backing with the ADLARITY (donepezil transdermal system) logo and 10 mg/day printed in black on the non-adhesive side. ADLARITY 10 mg/day is available in a carton of 4 (NDC 65038-056-03).
Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
Recent neuroscience experiments have brought inconsistent findings to light about the influence of neural activity in the alpha-frequency band (at ≈10 Hz) on the temporal dynamics of visual perception. Whereas strong alpha effects were found when perception was more based on endogenous factors, there were null-effects for alpha when perception relied more on objective physical parameters. In this Perspective, I open up a new view on neural alpha activity that resolves some important aspects of this controversy by interpreting alpha not as temporal processing of sensory inputs per se but above all as the observer's internal processing dynamics, their so-called perception sets. Perception sets reflect internally stored knowledge for how to organize and build up perceptual processes. They result from previous sensory experiences, are under top-down control to support goal-directed behavior, and root in pre-established neural networks that communicate through alpha frequency channels. I present three example cases from the recent neuroscience literature that show an influence of alpha-driven perception sets on the observer's visual-temporal resolution, object processing, and the processing of behaviorally relevant image content. Because alpha-driven perception sets can structure perception from its high-level aspects, like categories, down to its basic building blocks, like objects and time samples, they may have a fundamental impact on our conscious experience of the sensory world, including our perception of time itself.
The following adverse reactions have been identified during postapproval use of levetiracetam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.   
  
The following adverse reactions have been reported in patients receiving marketed levetiracetam worldwide. The listing is alphabetized: abnormal liver function test, acute kidney injury, anaphylaxis, angioedema, agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hepatitis, hyponatremia, muscular weakness, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases), panic attack, thrombocytopenia, and weight loss. Alopecia has been reported with levetiracetam use; recovery was observed in majority of cases where levetiracetam was discontinued. 

To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INTRODUCTION: Frailty and low physical performance are modifiable factors and, therefore, targets for interventions aimed at delaying driving cessation (DC). The objective was to determine the impact of frailty and physical performance on DC.
METHODS: Multisite prospective cohort of older drivers. The key inclusion criteria are as follows: active driver age 65-79 years, possessing a valid driver's license, without significant cognitive impairment, and driving a 1996 car or a newer model car. Of the 2,990 enrolled participants, 2,986 (99.9%) had at least one frailty or Short Physical Performance Battery (SPPB) measure and were included in this study. In total, 42% of participants were aged 65-69 years, 86% were non-Hispanic white, 53% were female, 63% were married, and 41% had a high degree of education. The Fried Frailty Phenotype and the Expanded Short Physical Performance Battery (SPPB) from the National Health and Aging Trends Study were utilized. At each annual visit, DC was assessed by the participant notifying the study team or self-reporting after no driving activity for at least 30 days, verified via GPS. Cox proportional hazard models, including time-varying covariates, were used to examine the impact of the SPPB and frailty scores on time to DC. This assessment included examining interactions by sex.
RESULTS: Seventy-three participants (2.4%) stopped driving by the end of year 5. Among women with a fair SPPB score, the adjusted hazard ratio (HR) of DC was 0.26 (95% confidence interval (CI) 0.10-0.65) compared to those with a poor SPPB score. For those with a good SPPB score, the adjusted HR of DC had a p-value of <0.001. Among men with a fair SPPB score, the adjusted hazard ratio (HR) of DC was 0.45 (95% CI 0.25-0.81) compared to those with a poor SPPB score. For men with a good SPPB score, the adjusted HR of DC was 0.19 (95% CI 0.10-0.36). Sex was not an effect modifier between frailty and DC. For those who were categorized into pre-frail or frail, the adjusted ratio of HR to DC was 6.1 (95% CI 2.7-13.8) compared to those who were not frail.
CONCLUSION AND RELEVANCE: Frailty and poor physical functioning are major risk factors for driving cessation. Staying physically active may help older adults to extend their driving life expectancy and mobility.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions refers to medicine, namely to dermatology, and can be used in pathological state of nails. A method of treating wherein a first composition containing a reducing agent of potential more than +20 mV and a second composition containing an oxidising agent of potential less than -50 mV are used. The compositions are applied to coat a nail separately consistently with the first composition applied in the beginning, and then the second composition. Either the first, or second, or third compositions which is a separate option for the compositions with the restoring and oxidising agents, containing a medicinal agent. Also, there is offered a kit comprising the first and second compositions which are arranged separately, and the medicinal agent which is included either in the first composition, or in the second composition, or optionally in the third composition. ^ EFFECT: inventions improves clinical effectiveness in the pathological state of nails due to intensified penetration of the medicinal agent through a nail plate so that the effective concentration of active particles reaches deeper layers of the nail plate, and also the same nail bed. ^ 45 cl, 9 tbl, 11 dwg, 10 ex
Cosmetic facial treatment delivery system with skincare benefit agents and iontophoresis micro-current zones are provided for delivering skincare treatments to multiple targeted areas of the skin to treat different concerns of an individual user. The system includes a sheet substrate with skincare agents and a micro-current generator secured to the sheet. The micro-current generator includes an oxidation agent, a reduction agent and a hydrogel with salt. The generator is activated by wetting to produce micro-current. The sheet is applied to skin. The micro-current generated facilitates delivery of skin benefit agents from the sheet by iontophoresis, or directly affects treatment by delivery of iontophoresis micro-current to the skin.
An automated reminder system 3 generates messages for customers 13-17 reminding them about a product renewal or service, e.g. vehicle servicing, swimming pool treatments, medical or veterinary appointments or re-ordering of medicines. A profile indicates a renewal profile and reference date e.g. purchase, invoice or reminder date, for each product associated with a customer, a single SMS or email message being generated for each customer, based on the current date, listing all relevant product renewals for the customer. The renewal profile may include a product identifier, renewal period and advance period. Templates may be provided for the message, different templates being available dependent on context, such as the number of renewals due. Client data, product or service data and invoices may be stored in a relational database, allowing automated building of the reminders list. The process may be run daily at the same time of day.
Proinflammatory T-lymphocytes recruited into the brain and spinal cord mediate multiple sclerosis (MS) and currently there is no cure for MS. IFN-γ-producing Th1 cells induce ascending paralysis in the spinal cord while IL-17-producing Th17 cells mediate cerebellar ataxia. STAT1 and STAT3 are required for Th1 and Th17 development, respectively, and the simultaneous targeting of STAT1 and STAT3 pathways is therefore a potential therapeutic strategy for suppressing disease in the spinal cord and brain. However, the pharmacological targeting of STAT1 and STAT3 presents significant challenges because of their intracellular localization. We have developed a STAT-specific single-domain nanobody (SBT-100) derived from camelids that targets conserved residues in Src homolog 2 (SH2) domains of STAT1 and STAT3. This study investigated whether SBT-100 could suppress experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. We show that SBT-100 ameliorates encephalomyelitis through suppressing the expansion of Th17 and Th1 cells in the brain and spinal cord. Adoptive transfer experiments revealed that lymphocytes from SBT-100-treated EAE mice have reduced capacity to induce EAE, indicating that the immunosuppressive effects derived from the direct suppression of encephalitogenic T-cells. The small size of SBT-100 makes this STAT-specific nanobody a promising immunotherapy for CNS autoimmune diseases, including multiple sclerosis.